Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
OtherEditorial

Why We Did What We Did: PSMA-PET/CT Selection Criteria for the VISION Trial

Phillip Hsin Kuo, Taylor Benson, Richard Messmann and Michael Groaning
Journal of Nuclear Medicine January 2022, jnumed.121.263638; DOI: https://doi.org/10.2967/jnumed.121.263638
Phillip Hsin Kuo
1 University of Arizona, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Taylor Benson
2 Novartis;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Messmann
2 Novartis;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Groaning
3 Amgen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading
PDF extract preview

This is a PDF-only article. The first page of the PDF of this article appears above.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 63 (7)
Journal of Nuclear Medicine
Vol. 63, Issue 7
July 1, 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Why We Did What We Did: PSMA-PET/CT Selection Criteria for the VISION Trial
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Why We Did What We Did: PSMA-PET/CT Selection Criteria for the VISION Trial
Phillip Hsin Kuo, Taylor Benson, Richard Messmann, Michael Groaning
Journal of Nuclear Medicine Jan 2022, jnumed.121.263638; DOI: 10.2967/jnumed.121.263638

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Why We Did What We Did: PSMA-PET/CT Selection Criteria for the VISION Trial
Phillip Hsin Kuo, Taylor Benson, Richard Messmann, Michael Groaning
Journal of Nuclear Medicine Jan 2022, jnumed.121.263638; DOI: 10.2967/jnumed.121.263638
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Editorial

  • Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Prostate Cancer: We have the answers
  • Radionuclide Evaluation of Brain Death in the Post-McMath Era, epilogue and enigmata.
Show more Editorial

Clinical (Radionuclide Therapy)

  • C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Patients with Advanced T-Cell Lymphoma
  • Long-term outcomes of submaximal activities of peptide receptor radionuclide therapy with 177Lu-DOTATATE in neuroendocrine tumour patients
  • Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study
Show more Clinical (Radionuclide Therapy)

Similar Articles

Keywords

  • Oncology: GU
  • PET/CT
  • radionuclide therapy
  • PET
  • PSMA
  • prostate cancer
  • selection criteria
  • theranostics
SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire